{
    "clinical_study": {
        "@rank": "68817", 
        "arm_group": {
            "arm_group_label": "Patients", 
            "description": "Administration of 123Iodine MIBG to the patients referred ."
        }, 
        "brief_summary": {
            "textblock": "Assessing 123 Iodine MIBG produced locally for safety while being used in clinical practice\n      to help in patient management decisions."
        }, 
        "brief_title": "Study Of the Safety of Locally Manufactured 123I-metaiodobenzylguanidine(MIBG) in Routine Clinical Use", 
        "completion_date": {
            "#text": "December 2018", 
            "@type": "Anticipated"
        }, 
        "condition": "Adrenergic Pathology", 
        "detailed_description": {
            "textblock": "We will be assessing for adverse reactions of patients injected with locally manufactured\n      123 Iodine MIBG. With monitoring of blood pressure and heart rate following injection and\n      any potential immediate side effects."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Patients with potential Adrenergic pathology\n\n        Exclusion Criteria:\n\n          -  Pregnant or breast feeding females\n\n          -  Hypersensitivity to MIBG"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "1 Month", 
            "sampling_method": "Non-Probability Sample", 
            "study_pop": {
                "textblock": "Those patients referred for MIBG assessment."
            }
        }, 
        "enrollment": {
            "#text": "1000", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "July 12, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01912040", 
            "org_study_id": "123Iodine MIBG"
        }, 
        "intervention": {
            "arm_group_label": "Patients", 
            "description": "Patients will be administered the locally produced 123 Iodine MIBG", 
            "intervention_name": "Administration of  123Iodine MIBG", 
            "intervention_type": "Drug", 
            "other_name": "None applicable"
        }, 
        "intervention_browse": {
            "mesh_term": [
                "Iodine", 
                "Cadexomer iodine", 
                "3-Iodobenzylguanidine"
            ]
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "Safety profile", 
            "locally produced 123 Iodine MIBG"
        ], 
        "lastchanged_date": "July 29, 2013", 
        "location": {
            "facility": {
                "address": {
                    "city": "Halifax", 
                    "country": "Canada", 
                    "state": "Nova Scotia", 
                    "zip": "B3H2Y5"
                }, 
                "name": "Capital District Health Authority"
            }, 
            "investigator": {
                "last_name": "Andrew Ross, MD", 
                "role": "Principal Investigator"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "Canada"
        }, 
        "number_of_groups": "1", 
        "official_title": "A Prospective, Open Label, Single Arm Cohort Study to Assess the Frequency of Adverse Reactions of Locally Manufactured 123I-metaiodobenzylguanidine in Routine Clinical Use", 
        "overall_contact": {
            "email": "aross@dal.ca", 
            "last_name": "Andrew Ross, MD", 
            "phone": "902-473-7770"
        }, 
        "overall_contact_backup": {
            "email": "chrisitna.kelly@cdha.nshealth.ca", 
            "last_name": "Christina Kelly, B.T.", 
            "phone": "902-473-4377"
        }, 
        "overall_official": {
            "affiliation": "Division Head, Nuclear Medicine", 
            "last_name": "Andrew Ross, MD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "Canada: Health Canada", 
            "has_dmc": "No"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "December 2018", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "Safety profile of the 123Iodine MIBG", 
            "safety_issue": "Yes", 
            "time_frame": "BP and Heart rate for 24 hours  after injection."
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01912040"
        }, 
        "responsible_party": {
            "investigator_affiliation": "Capital District Health Authority, Canada", 
            "investigator_full_name": "Andrew Ross", 
            "investigator_title": "Division Head, Nuclear Medicine", 
            "responsible_party_type": "Principal Investigator"
        }, 
        "source": "Capital District Health Authority, Canada", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Capital District Health Authority, Canada", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "July 2006", 
        "study_design": "Observational Model: Cohort, Time Perspective: Prospective", 
        "study_type": "Observational", 
        "verification_date": "July 2013"
    }
}